Clinical trials for Rabies

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Rabies. For all clinical trials, go to clinical trials search

This list shows clinical trials for Rabies

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Rabies
Title Recruitment status Location
A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients - zolpidem in brain damage Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin) ENABLE-ALL (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver DiseasE – All Subjects Withdrawing From ENABLE 1 and 2 through Lack of Response) - ENABLE ALL Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) - ENABLE 1 Not Recruiting United Kingdom
TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin) ENABLE-ALL (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver DiseasE – All Subjects Withdrawing From ENABLE 1 and 2 through Lack of Response) - ENABLE ALL Not Recruiting United Kingdom
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral infection for the prevention or attenuation of COPD symptoms caused by respiratory viruses - Phase II: Inhaled SNG001 in COPD subjects Authorised United Kingdom

Page last reviewed: 06/12/2012

Next review due: 06/12/2014